The evolution of research themes from 1993 to 2023—traced through co-occurrence networks and cluster analyses—shows clear transitions: from ACE inhibitors to ARNIs and SGLT2 inhibitors; from short-term survival to long-term, multimorbidity management; from acute coronary care to chronic HF optimization; from ejection fraction metrics to multi-omics biomarkers; and from traditional trials to AI-driven prediction models. This evidence concerns the gene ACE and hydrops fetalis.